Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Exicure Inc is a biotechnology business based in the US. Exicure shares (XCUR) are listed on the NASDAQ and all prices are listed in US Dollars. Exicure employs 40 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $2.07 |
|---|---|
| 52-week range | $2.00 - $59.40 |
| 50-day moving average | $3.74 |
| 200-day moving average | $11.61 |
| Wall St. target price | $93.75 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.62 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.07 from 2022-07-01
| 1 week (2022-06-24) | 1,442.47% |
|---|---|
| 1 month (2022-05-30) | N/A |
| 3 months (2022-03-30) | N/A |
| 6 months (2021-12-31) | 924.25% |
| 1 year (2021-07-02) | 35.29% |
|---|---|
| 2 years (2020-07-02) | -16.53% |
| 3 years (2019-07-03) | 2.55 |
| 5 years (2017-06-29) | N/A |
| Revenue TTM | $1.1 million |
|---|---|
| Gross profit TTM | $-48,839,000 |
| Return on assets TTM | -54.81% |
| Return on equity TTM | -225.14% |
| Profit margin | 0% |
| Book value | $0.79 |
| Market capitalisation | $8.5 million |
TTM: trailing 12 months
We're not expecting Exicure to pay a dividend over the next 12 months.
Exicure's shares were split on a 1:30 basis on 29 June 2022. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Exicure shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Exicure shares which in turn could have impacted Exicure's share price.
Over the last 12 months, Exicure's shares have ranged in value from as little as $2 up to $59.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Exicure's is 1.2461. This would suggest that Exicure's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Exicure, Inc. , a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S. A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.